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doi:10.101Osteochondroma after Hematopoietic Stem Cell
Transplantation in Childhood. An Italian Study on
Behalf of the AIEOP-HSCT Group
Maura Faraci,1 Francesca Bagnasco,2 Paola Corti,3 Chiara Messina,4 Franca Fagioli,5
Marta Podda,6 Arcangelo Prete,7 Desire` Caselli,8 Edoardo Lanino,1 Giorgio Dini,1
Roberto Rondelli,7 Riccardo Haupt,2 on behalf of the AIEOP-HSCT GroupA retrospective study was conducted among Italian children treated with hematopoietic stem cell transplant
(HSCT) to evaluate the incidence and risk factors in the development of osteochondroma (OC). OC
occurred in 27 patients who received autologous or allogeneic HSCT. The estimated 5-, 10-, and 15-year
cumulative risk of developing OCwas 0.5%, 3.2%, and 6.1%, respectively. Analysis of cumulative risk stratified
by the various risk factors revealed that male sex (P5.026), autologous HSCT (P5.001), age at HSCT (#3
years) (P\.0001), and total body irradiation (TBI) (P\.0001) significantly affected the risk of OC. Multivar-
iate analysis, restricted only to tumor types with at least 1 case of OC, showed that earlier age at HSCT
(P 5.0004) and TBI (P\.0001) were the only factors that were significantly associated with OC.
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Hematopoietic stem cell transplantation (HSCT)
represents the therapeutic choice for curing some
types of malignant and nonmalignant diseases. How-
ever, although we attempt to cure the patient, the
high-dose chemo- and radiotherapy that are adminis-
tered may increase the risk of side effects on virtually
any organ or system. In particular, the main skeletal
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Osteochondroma (OC) is the most common
benign bone tumor thatmay develop in any bonewhere
growth occurs by endochondral ossification. The
metaphyseal regions of the long bones are themost fre-
quently affected, and the distal femur, as well as the
proximal tibia or humerus are the most common local-
izations. OC generally presents as a single lesion; how-
ever, multiple occurrences may develop in the context
of hereditary multiple osteochondromatosis [1].
Only a few reports are currently available on OC
occurrence in cancer survivors [2-4]. Most of them are
case reports or case series, or refer to selected popula-
tions exposed to radiotherapy inwhoma high incidence
of OC has been reported. The onlymanuscript that an-
alyzeda large cohort of transplantedpatients, regardless
of the conditioning regimen they received, didnot dem-
onstrate that total body irradiation (TBI) had any signif-
icant effect, whereas only autologousHSCTwas found
to be significantly associated with high OC risk [3].
Some authors suggested that the use of growth hor-
mone (GH) replacement therapy in patients treated
with TBI may increase the incidence of OC [5].
To further evaluate the incidence of OC after
HSCT in a large cohort of transplanted children,
and to assess the effect of various risk factors, we
reviewed data from nine Italian HSCT centers of the
Italian Association of Pediatric Oncology and Oncol-
ogy (AIEOP).1271
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All children transplanted at any of the 21 AIEOP-
HSCT centers, included in the Italian HSCT Regis-
try, and who survived at least 1 year after transplant,
were eligible for this study.
Data were available from the AIEOP-HSCT Reg-
istry, which collects prospectively information on de-
mographics, type of primary diagnosis, date and type
of transplant, conditioning regimen, occurrence and
grade of acute and chronic graft-versus-host disease
(aGVHD, cGVHD), date and status at last follow-
up, and date of any second transplant. For the purposes
of this study, primary diagnoses were grouped into 3
categories (ie, solid tumors, hematologic malignancies,
and nonmalignant diseases), whereas 2 types of HSCT
were defined (ie, autologous and allogeneic), and last, 2
categories based on age at HSCTwere identified using
3 years of age as the cut off, ie, .3 or\3 years of age.
With regard to data on conditioning regimens, they
were grouped into 2 categories based upon the admin-
istration or absence of administration of TBI. Data re-
garding type of chemotherapy were not taken into
consideration because drugs and schedules changed
a great deal throughout the study period.
Specifically for this study, each center was required
to report on all eligible patients in whom OC was
diagnosed during follow-up. In case of OC, data were
further collected on the date of OC, modality of diag-
nosis, site of OC, previous therapy with GH, clinical
approach, and need for surgical treatment. As for
methods of diagnosis, it could have been accidental or
on clinical bases. In more detail, OC was accidental if
observed after radiologic imaging performed for other
reasons (eg, bone age, standard chest X-ray, or to ex-
clude bone metastases), or on clinical bases if imaging
(standardX-ray)was performed after patients complain
of symptoms (eg, bone deformities, vascular or neuro-
logic compromise, or mechanical joint problems).
This retrospective study was approved by the
AIEOP-HSCT board, and data were collected anony-
mously. Moreover, all the HSCT patients or their
guardians had previously signed a consent form allow-
ing us to use their data for clinical research purposes.
The procedures we followed were in accordance with
the ethical standards and with the Helsinki Declara-
tion. On the basis of Italian rules, no specific informed
consent was required for this study.Statistical Analysis
Descriptive statistics were reported in terms of ab-
solute frequencies and percentages for qualitative data,
and the Pearson’s chi-square test or Fisher’s exact test,
if appropriate, were applied to compare proportions.
Quantitative data were described in terms of median
values and range because of their nonnormal (Gaussian)
distribution.Accordingly, comparisons betweengroupswere performed by the nonparametric Mann-Whitney
U-test (MW), or by the Kruskal-Wallis (KW) test
when.2 groups had to be compared.
Follow-up was censored at the date of the last fol-
low-up or at the date of second HSCT (for patients
who received more than 1 transplant). The cumulative
risk of OC after HSCT was evaluated by the Kaplan-
Meier method, and differences between groups were
assessed by the log-rank test. The Cox proportional
hazard model was used for modeling the combined ef-
fect of the various prognostic factors. Because GVHD
can only occur in allogeneic recipients, it was not in-
cluded in the multivariable analysis of this model.
The hazard ratio (HR) with the 95%CI was calculated
tomeasure the effect of each predictor compared to the
reference value, and the likelihood ratio test (LRT)
was used to assess the effect of predictors. Proportional
hazard assumption was tested using scaled Schoenfeld
residuals against log of time.
All testswere 2 tailed and aP value\ .05was consid-
ered statistically significant. The statistical software
‘‘Statistica’’ (release 6.0, StatSoft Corporation, Tulsa,
OK) and the software ‘‘Stata’’ (release 7.0, StataCorp
2001,CollegeStation,TX)wereused for all the analyses.RESULTS
Nine of the 21 AIEOP-HSCT centers (43%)
agreed to participate in this study. However, alone
they had performed 56% (n5 3469) of the 6180 Italian
transplants registered during the study period. These
centers provided the data for the 1632 children who
were eligible for this study, and among them a total
of 27 OC (1.6%) were reported.
Table 1 reports the characteristics of patients strat-
ified by OC status. Compared to children without OC,
those with OC were more likely to be males (81%;
n5 22; versus 59%; n5 942; P5 .017), to be younger
at diagnosis (median age 2.7 years versus 5.2 years;
P5 .0003), and at HSCT (median age 4.3 years versus
7.7 years; P\ .0001), and to have received TBI as part
of their conditioning regimen (96% n5 26; versus
37% n5 570; P\ .001). No differences between chil-
dren with or withoutOCwere foundwith regard to un-
derlying disease (P5 .065), donor type (P5 .060), and
aGVHD or cGVHD (P5 .687 and P5 .475, respec-
tively). As for the tumor type, among childrenwith solid
tumors, all the OC cases had had neuroblastoma (NB).
As shown in Table 2, OC occurred in 6 (37%) of the 16
NB patients irradiated when #3 years old, and in 4
(10%) of those irradiated thereafter. Among children
with other solid tumors, none were irradiated when
#3 years old and none (0%) of the 6 irradiated when
.3 years old developed OC. As for hematologic dis-
eases, similar to NB patients, 5 (20%) of the 25
children irradiated before the age of 3 years developed
OC.
Table 1. Characteristics of 1632 Patients Undergoing HSCTat 9 AIEOP-HSCT Centers
Entire Cohort Patients with OC Patients without OC P*
Sex, n (%) .017
Male 964 (59) 22 (81) 942 (59)
Female 668 (41) 5 (19) 663 (41)
Median age at diagnosis, years (range) 5.1 (20.2†-18.2) 2.7 (0.4-10.3) 5.2 (2 0.2-18.2) .0003
Median age at OC, years (range) — 13.3 (3.9-21.5) — —
Median interval OC-HSCT, years (range) — 8.9 (1.9-13.8) — —
Median age at HSCT, years (range) 7.6 (0.1-18.9) 4.3 (0.7- 10.6) 7.7 (0.1-18.9) <.0001
Age at HSCT, n (%) <.001
> 3 years 1391 (85) 15 (56) 1376 (86)
# 3 years 241 (15) 12 (44) 229 (14)
Underlying diseases, n (%) .065
Solid tumors 624 (38) 10 (37) 614 (38)
NB 296 (47) 10 (100) 286 (47)
Bone tumors 116 (19) 116 (19)
CNS tumors 82 (13) 82 (13)
HD 44 (7) 44 (7)
Soft tissue sarcomas 38 (6) 38 (6)
Wilms tumor 32 (5) 32 (5)
Other solid tumors 16 (3) 16 (3)
Hematologic malignancies 798 (49) 17 (63) 781 (49)
ALL 421 (53) 8 (47) 413 (53)
AML 242 (30) 6 (35) 236 (30)
NHL 60 (8) 2 (12) 58 (7)
CML 41 (5) 1 (6) 40 (5)
MDS 19 (2) 19 (3)
Histiocytosis 15 (2) 15 (2)
Nonmalignant diseases 210 (13) 0 210 (13)
Inborn errors 141 (67) 141 (67)
SAA 69 (33) 69 (33)
Donor type, n (%) .060
Autologous 856 (52) 19 (70) 837 (52)
Allogeneic 776 (48) 8 (30) 768 (48)
HLA identical
related donor
492 (63) 6 (75)
Unrelated donor 242 (31)
HLA mismatched-related donor 37 (5) 1 (12.5)
Syngenic 5 (1) 1 (12.5)
TBI, n (%) <.001
No 1036 (63) 1 (4) 1035 (64)
Yes 596 (37) 26 (96) 570 (36)
Acute GVHD,‡ n (%) .687
No 175 (25) 1 (12) 174 (26)
Yes 512 (75) 7 (88) 505 (74)
Chronic GVHD,§ n (%) .475
No 433 (63) 4 (50) 429 (63)
Yes 252 (37) 4 (50) 248 (37)
Total 1632 27 1605 —
ALL indicates acute lymphoblastic leukemia; NB, neuroblastoma; AML, acutemyelogenous leukemia ; CNS tumors, central nervous system tumors; SAA,
severe aplastic anemia; NHL, Non-Hodgkin lymphoma; HD, Hodgkin lymphoma; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome;
TBI, total body irradiation; GVHD, graft-versus-host disease; OC, osteochondroma; HSCT, hematopoietic stem cell transplantation.
*Pearson’s chi-square or Fisher’s exact test or Mann-Whitney U-test were used to compare the two groups of patients with and without OC.
†One patient with Neuroblastoma had prenatal diagnosis.
‡Evaluable for 776 allogeneic donors, 89 missing data.
§Evaluable for 776 allogeneic donors, 91 missing data.
Biol Blood Marrow Transplant 15:1271-1276, 2009 1273OC in Children after HSCTAmong children with OC, the diagnosis had been
based on clinical symptoms in 16 of them (59%): 13
had had bone protuberances, and 3 complained of pe-
ripheral neurologic symptoms (paraesthesia). Diagno-
sis was accidental in the remaining 11 patients (41%),
that is, followingX-ray examination performed to eval-
uate bone age (n5 3), pulmonary disease (n5 2), bone
metastases (n5 1), orthopedic problems (n5 1), or for
other unspecified causes (n5 4).
OCoccurred as a single lesion in themajority of pa-
tients (n5 17; 63%), whilemultiple lesions (range: 2-6)were identified in 10 patients. Overall, a total of 43 lo-
calizations were described as follows: 39 (91%) in the
metaphyseal region of the long bones (14 femurs; 10
tibias; 5 ribs; 5 fibulas; 3 radii; and 2 ulnas) and 4 (9%)
in flat bones (2 iliac bones; 1metacarpus; and 1 scapula).
None had a family history of OC. Three patients
had received GH replacement therapy and they devel-
oped OC 0.1, 0.8, and 3.2 years after GH therapy, and
5.1, 8.7, and 9.7 years after HSCT, respectively.
In general, a wait-and-see or symptomatic thera-
peutic approach was applied to all patients. Surgery
Table 2. Distribution of TBI by Underlying Diseases among
241Children at#3Years ofAgeSinceHSCTand 1391Children
at >3 Years of Age Since HSCT
Age at HSCT #3 Years Age at HSCT >3 Years
Underlying diseases
TBI Yes, n
(n OC, %)
TBI No, n
(n OC, %)
TBI Yes, n
(n OC, %)
TBI No, n
(n OC, %)
NB 16 (6, 37) 74 (0) 42 (4, 10) 164 (0)
Other solid tumors 0 (0) 20 (0) 6 (0) 302 (0)
Hematologic
malignancies
25 (5, 20) 65 (1, 1) 504 (11, 2) 204 (0)
Nonmalignant
diseases
1 (0) 40 (0) 2 (0) 167 (0)
Total 42 (11, 26) 199 (1, 1) 554 (15, 3) 837 (0)
TBI indicates total body irradiation; NB, neuroblastoma; OC, osteo-
chondroma; HSCT, hematopoietic stem cell transplantation.
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occurred, such as intractable bone pain, or compres-
sion on nervous-vascular structures. At follow-up,
5 subjects (19%) had undergone surgical OC resection
after a median of 9 months (range: 0-4.8 years). None
had malignant evolution of OC.
Length of follow-up after HSCT ranged between
1.1 and 29.1 years (median, 4.8 years). The estimated
5-, 10-, and 15-year cumulative risk of developing
OC for the entire cohort was 0.5% (95% confidence
interval [CI] 0.2-1.3), 3.2% (95% CI 2.1-5.1), and
6.1% (95% CI 4.0-9.1), respectively (Figure 1). Strat-
ification of the analysis by various risk factors showed
that male sex, young age at HSCT, treatment with
TBI, and autologous type of HSCT were statistically
significant risk factors for OC (Table 3). In more de-
tail, and considering the cumulative risk at 15 years af-
terHSCT, the probability of developingOCwas 8.6%
for males versus 2.1% for females (P5 .026); 20.2%
for children transplanted at age #3 years versus
3.9% among those transplanted later (P \ .001);
12.1% for patients treated with TBI versus 0.2% for
those who did not receive TBI (P\ .001); 11.8% forFigure 1. Estimated 15-year cumulative risk (Kaplan-Meier failure esti-
mate) of developing OC after HSCT.autologous recipients versus 2.7% among allogeneic
recipients (P 5 .001). With regard to the underlying
disease, there was a significant difference in the prob-
ability to develop OC across the 3 disease categories
evaluated (P 5 .006). This difference remained signif-
icant also if categories in which no OC were docu-
mented (ie, nonmalignant hematologic diseases and
solid tumors other than NB) were excluded from the
analysis (data not shown).
The type of underlying disease was not taken into
consideration in the Cox proportional hazard model of
the entire cohort (Table 4), in particular, because of
the absence of OC events among patients with nonma-
lignant diseases and solid tumors other than NB. In
this model, only age at HSCT, type of HSCT, and
TBI were found to be significantly associated with an
increased risk of OC. In more detail, children trans-
planted at a younger age (#3 years) had a 6.08-fold
(95% CI 2.78-13.29) increased risk of OC. If type of
HSCT was evaluated, patients who received autolo-
gous HSCT had a 2.67-fold (95% CI 1.13-6.25)
increased risk of OC compared to those who received
allogeneic HSCT. Finally, we confirm that TBI signif-
icantly affects the probability of OC, with a 32.99-fold
(95% CI 4.44-245.42) increased OC risk among chil-
dren treated with TBI. In a further analysis, the Cox
model was restricted to the only 2 tumor categories
in which at least 1 OC was reported (ie, NB and hema-
tologic malignancies). Also in this model, age at
HSCT and TBI remained as the only significant risk
factors. The effect of NB was not significant
(P5 .3995), even if NB patients had a 1.53 HR com-
pared to children with hematologic disease.DISCUSSION
To our knowledge, this is largest series of trans-
planted children in which the risk factors for OC fol-
lowing HSCT have been analyzed. Moreover, this
cohort has been followed up for a longer period of
time (median 4.8 years) compared to what has been
(2.6 years) reported in the other large cohort described
to date [3].
Even though univariate analyses showed that
several factors were significantly related to the risk of
developing OC, multivariate analyses revealed that
young age at transplant and treatment with TBI were
the only independent risk factors significantly related
to the probability of developing OC. Autologous
transplant was also found to be an independent risk
factor, but with a less significant value, and only
when the entire cohort was analyzed. We believe that
autologous transplant was a confounding factor and
that our finding was not because of the procedure
‘‘per se,’’ but to the fact that in our series, 95% of the
patients who developed OC after autologous HSCT
Table 3. Cumulative Risk of Developing OC in 1632 HSCT Patients, Shown by Various Risk Factors
%Cumulative Risk (95%CI)
Risk Factor No. of OC (%) At 5 Years At 10 Years At 15 Years P
Sex .026
Male 22 (81) 0.5 (0.2-1.6) 4.0 (2.3- 6.7) 8.6 (5.4-13.3)
Female 5 (19) 0.5 (0.1-2.2) 2.1 (0.8- 5.1) 2.1 (0.8- 5.1)
Underlying disease .006
Solid tumors 10 (37) 0.0 6.6 (3.1-13.7) 12.9 (6.4-25.2)
Hematologic 17 (63) 0.9 (0.4-2.3) 3.3 (1.8- 5.9) 6.8 (3.9-11.5)
Nonmalignant 0 — — —
Age at HSCT <.001
#3 years 12 (44) 1.3 (0.3-4.9) 13.3 (7.1-24.1) 20.2 (10.9-35.6)
>3 years 15 (56) 0.4 (0.1-1.2) 1.6 (0.8- 3.1) 3.9 (2.2- 6.7)
TBI <.001
No 1 (4) 0.2 (0.1-1.2) 0.2 (0.1-1.2) 0.2 (0.1-1.2)
Yes 26 (96) 0.9 (0.4-2.6) 6.6 (4.1-10.4) 12.1 (8.1-17.9)
Donor type .001
Autologous 19 (70) 0.4 (0.1-1.8) 6.5 (3.8-11.1) 11.8 (7.2-18.9)
Allogeneic 8 (30) 0.6 (0.2-1.8) 1.1 (0.5-2.8) 2.7 (1.3-5.8)
Acute GVHD .489
No 1 (12) 0.8 (0.1-5.3) 0.8 (0.1-5.3) 0.8 (0.1-5.3)
Yes 7 (88) 0.6 (0.2-2.5) 1.6 (0.6-4.2) 4.8 (2.1-11.1)
Chronic GVHD .427
No 4 (50) 0.7 (0.2-2.7) 0.7 (0.2-2.7) 3.7 (1.1-11.3)
Yes 4 (50) 0.7 (0.1-4.7) 2.7 (0.8-8.2) 4.2 (1.5-11.3)
Total 27 0.5 (0.2-1.3) 3.2 (2.1-5.1) 6.1 (4.0- 9.1) —
TBI, total body irradiation; GVHD, graft-versus-host disease; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; OC, osteochon-
droma.
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years old at the time of transplant. Among these pa-
tients, 60% had had NB and had been treated before
1991 when the conditioning regimens for that disease
included TBI. This procedure is no longer in use, and
therefore we postulate that this finding will not be con-
firmed when longer follow-up will be available for
children more recently treated with autologous
HSCT, but with no TBI-containing regimens. This
observation is further confirmed by the Cox analysis
restricted to only tumor types in which at least 1 case
of OC was documented (ie, NB and hematologic
malignancies) and in which type of transplant was no
more significant. In this analysis also the NB was not
found to be a risk factor for OC.
Most of the reports on OC after HSCT refer to se-
lected populations (eg, those treated with TBI [2,4] or
any type of radiation [6]). These authors reported that
younger children (\5 years [2] or\8 years [7]) are at
higher risk of radiation-induced OC. On the other
hand, the only other study that included all trans-
planted children was the 1 by Bordigoni et al. [3],
who found autologous transplant to be the only signif-
icant risk factor. This study was based on 8 cases of 249
transplanted children conditioned either with TBI or
busulfan (Bu).
We believe that our study, which is the largest
reported to date, is useful to confirm the detrimental
effect of TBI, in particular, when given at a younger
age. In fact, the skeletal damage caused by TBI, espe-
cially when administered at a young age is recognized
[2,8]. Because TBI leads to growth impairmentthrough peripheral lesions to the bones and cartilage,
the epiphysis remains open longer than usual, thus
allowing more time for OC to develop [6].
Another observation regards our estimation of
a 6.1% cumulative risk of developingOC 15 years after
transplant. In particular, we observed an 11.8% cumu-
lative risk after autologous HSCT and only 2.7% cu-
mulative risk after allogeneic HSCT. These results
are lower compared to estimates by Bordigoni et al.
[3], who reported a 31.7% and 13.0% 12-year cumula-
tive risk after autologous and allogeneic transplant,
respectively. We suggest that these differences might
be because of a possible underreporting bias in our
multicenter study, but also to the fact that our study
includes all types of conditioning regimens, unlike
Bordigoni et al. [3], who only took into consideration
regimens including either TBI or Bu.
Last, in our series we did not document any malig-
nant degeneration of OC. This event is described as
occurring more frequently in case of hereditary multi-
ple osteochondromatosis (2.5%) [1]. Moreover, the
only 3 reported patients who underwent malignant
transformation of OC had also previously received
local high-dose irradiation to treat their solid tumors
[5,9,10].
Harper et al. [11] and Bordigoni and colleagues [3]
suggested that children treated with GH replacement
therapy had a tendency to develop early OC and after
less time following HSCT, because GH therapy might
be a trigger feature in radiotherapy-disturbed epiphy-
ses. Sanders et al. [5] demonstrated that patients re-
ceiving GH developed OC after a longer period of
Table 4. Multivariate Analysis on the Effect of Various Risk
Factors on the Hazard Function of Developing OC in 1632
HSCT Patients and in 1094 HSCT Patients with NB or
Hematologic Malignancies
Entire Cohort
Factor HR CI 95% LR P
Sex 3.14 .0762
Female 1.00
Male 2.26 0.85-6.03
Age at HSCT 17.59 <.0001
>3 years 1.00
#3 years 6.08 2.78-13.29
Donor type 5.49 .0191
Allogeneic 1.00
Autologous 2.67 1.13-6.25
TBI 33.48 <.0001
No 1.00
Yes 32.99 4.44-245.42
LRTof model 5 65.4; P < .0001
Only patients with NB or Hematologic Malignancies
Factor HR CI 95% LR P
Sex 2.81 .0937
Female 1.00
Male 2.18 0.82-5.80
Age at HSCT 12.31 .0004
>3 years 1.00
#3 years 5.08 2.14-12.10
Donor type 2.83 .0926
Allogeneic 1.00
Autologous 2.27 0.88-5.87
TBI 18.67 <.0001
No 1.00
Yes 18.23 2.41-137.65
Underlying disease 0.71 .3995
Hematologic 1.00
NB 1.53 0.57-4.10
LRTof model5 44.2; P < .0001
TBI indicates total body irradiation; HSCT, hematopoietic stem cell
transplantation; CI, confidence interval; HR, hazard ratio; NB, neuro-
blastoma; LR, likelihood ratio; LRT, likelihood ratio test; OC, osteochon-
droma.
1276 Biol Blood Marrow Transplant 15:1271-1276, 2009M. Faraci et al.time following HSCT, but they were younger at
HSCT than non-GH treated patients. In our experi-
ence, only 3 patients with OC had received GH re-
placement therapy, and none of them developed
malignant degeneration of their OC. Unfortunately,
however, we could not provide any information on
the GH-related risk of developing OC because this in-
formation was not available in the Italian HSCT regis-
try.
Regarding the guidelines for monitoring OC, we
agree with Taitz et al. [2], who believe that annual or
biannual screening by plain radiologic examination isnot cost-effective, and that furthermore, it is danger-
ous (exposure to further radiation) and psychologically
harmful. We believe that only careful clinical evalua-
tion and follow-up, especially in patients treated with
TBI at a young age, would be useful for the early diag-
nosis of OC , as well as to evaluate the need for surgical
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